Rosalind Advisors, Inc. TRVI — TREVI THERAPEUTICS INC

Ownership history in Rosalind Advisors, Inc.  ·  9 quarters on record

AI Ownership Summary

Rosalind Advisors, Inc. reported TREVI THERAPEUTICS INC (TRVI) in 9 quarterly 13F filings from 2023 Q4 through 2025 Q4. Peak portfolio weight reached 3.19% in 2024 Q2. The latest visible filing shows TRVI at 0.44% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this TRVI ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Rosalind Advisors, Inc.'s position in TREVI THERAPEUTICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

TRVI was reported at 0.44% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
3.19% in 2024 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

TRVI stock page Rosalind Advisors, Inc. fund profile Rosalind Advisors, Inc. full holdings
How Rosalind Advisors, Inc. held TRVI — position size vs. price
% of Fund (quarterly)    TRVI price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 9 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 UNCHANGED — — — 100,000 — 0% 0.44% $1.3M 2026-02-12 $10.94
2025 Q3 REDUCED 66.7% +40.1% ❌ 100,000 -200,000 -66.7% 0.31% $915K 2025-11-13 $11.46
2025 Q2 REDUCED 51.1% +63.6% ❌ 300,000 -312,901 -51.1% 0.78% $1.6M 2025-08-14 $7.49
2025 Q1 REDUCED 42.3% -13.0% ✅ 612,901 -449,599 -42.3% 1.87% $3.9M 2025-05-14 $6.19
2024 Q4 ADDED — — — 1,062,500 +312,500 +41.7% 2.24% $4.38B 2025-02-11 $3.96
2024 Q3 REDUCED 46.1% +22.8% ❌ 750,000 -641,577 -46.1% 1.60% $2.5M 2024-10-30 $3.06
2024 Q2 ADDED — — — 1,391,577 +465,561 +50.3% 3.19% $4.1M 2024-07-12 $2.80
2024 Q1 REDUCED 50.3% -16.2% ✅ 926,016 -936,409 -50.3% 2.99% $3.19B 2024-04-25 $2.54
2023 Q4 INITIATED — — — 1,862,425 — — 2.06% $2.5M 2024-02-14 $2.12

🏢 Other funds also holding TRVI

As of 2026 Q1 — sorted by position size

NEA Management Company, LLC 3Y 7Y 8.97% ACORN CAPITAL ADVISORS, LLC 7.27% Pivotal bioVenture Partners Investment Advisor LLC 3Y 6.63% Vivo Capital, LLC 3Y 7Y 5.07% Artia Global Partners LP 3Y 4.81% KVP Capital Advisors, LP 3.69% Frazier Life Sciences Management, L.P. 3Y 3.05% MPM BioImpact LLC 3Y 3.04% SUPERSTRING CAPITAL MANAGEMENT LP 2.14% Octagon Capital Advisors LP 3Y 1.96%

FAQ About Rosalind Advisors, Inc. and TRVI

These are the practical questions this page is built to answer before you even open the full history table.

How long has Rosalind Advisors, Inc. reported owning TRVI?

Rosalind Advisors, Inc. reported TRVI across 9 quarterly 13F filings, from 2023 Q4 through 2025 Q4.

What was the largest reported TRVI position in Rosalind Advisors, Inc.'s portfolio?

The largest reported portfolio weight for TRVI was 3.19% in 2024 Q2.

What is the latest reported TRVI position on this page?

The most recent filing on this page is 2025 Q4, when Rosalind Advisors, Inc. reported 100,000 shares, equal to 0.44% of portfolio, with an estimated market value of $1.3M.

What does the chart on this TRVI ownership page compare?

The chart compares Rosalind Advisors, Inc.'s quarterly TRVI portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Rosalind Advisors, Inc. time their TRVI position?

Based on 13F filing dates vs. subsequent TRVI price moves, Rosalind Advisors, Inc. correctly timed 4 out of 8 reported position changes (50%). The annualised alpha on TRVI relative to SPY over the holding period was +92.2%.

← Back to Rosalind Advisors, Inc. Holdings